Rima Zahr is a Nephrology physician affiliated with University of Tennessee Health Science Center. OpenAlex indexes 51 publications with 630 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VertexProgram year20251 paymentResearch$34,897openpaymentsdata.cms.gov ↗
- Travere Therapeutics, Inc.Program year20252 payments
- VertexProgram year20241 paymentResearch
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
41.8%Short-acting sulfonamides23.9%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor17.9%Valganciclovir Hcl100%Part D<11 patientsCardiovascular
31.3%Calcium channel blocker31.3%Amlodipine Besylate100%Part D<11 patientsMetabolism & gastrointestinal
26.9%H2 blocker26.9%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Genetic modifiers of Sickle Cell Kidney Disease
University of Tennessee Health Sci Ctr
FY2026$166,559K23HL157554 - Genetic modifiers of Sickle Cell Kidney Disease
University of Tennessee Health Sci Ctr
FY2025$168,179K23HL157554
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Increased Endothelin-1 and High-Risk APOL1 Variants Contribute to Albuminuria in Pediatric and Young Adults with Sickle Cell Anemia
Clinical Journal of the American Society of Nephrology
2026 - The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia‐Associated Kidney Function
American Journal of Hematology
2026 - Hospital-associated acute kidney injury in pediatric sickle cell disease: prevalence and NSAID exposure
Blood Red Cells & Iron
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Csaba Kovesdy, MD
University of Tennessee Health Science Center
Samuel Dagogo-Jack, MD
University of Tennessee Health Science Center
Lucas Elijovich, MD
University of Tennessee Health Science Center
Lucien Nedzi, MD
University of Tennessee Health Science Center
Andrew Levey, MD
Tufts Medical Center
Laura Svetkey, MD
Duke University
Prasad Devarajan, MD
Cincinnati Children's Hospital Medical Center
Rajesh V. Thakker
Queen Mary University of London
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”